Efficacy, Safety, and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Prevention of Symptomatic COVID-19: 15-Month Final Analysis of the PROVENT and STORM CHASER Trials.

Infect Dis Ther · 2024 · PMC11128422 · PMID 38703336

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

marginally significantno p-value reported

However, a marginally significant RRR of 73.2% (95% CI 27.1, 90.1) was observed in an ad hoc analysis of the subgroup of participants with a negative or missing SARS-CoV-2 RT-PCR status at baseline.

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.